Mizuho analyst Ann Hynes last night initiated coverage of UnitedHealth Group with a Buy rating and $270 price target. The analyst sees high long-term earnings visibility given underlying market growth, its leading market position in Medicare, growth and margin expansion potential in Medicare Advantage, potential market share gains in Medicaid, and diversification into healthcare services.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here